Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

OBJECTIVE--To examine the association between the serum lipoprotein (a) concentration and subsequent coronary heart disease. DESIGN--Prospective case-control study based on a six year follow up of a general population sample of men aged 50 at baseline in 1983-4. Serum samples were frozen at the time of the baseline examination and kept at -70 degrees C for six years, after which the lipoprotein (a) concentrations in the samples were measured in cases and controls. SETTING--City of Gothenburg, Sweden. SUBJECTS--26 Men, from a general population sample of 776 men, who had sustained a myocardial infarction or died of coronary heart disease during the six years and 109 randomly selected controls from the same sample who had remained free of myocardial infarction. In neither cases nor controls was there a history of myocardial infarction at baseline. MAIN OUTCOME MEASURES--Proportion of myocardial infarction or deaths from coronary heart disease, or both, in relation to the serum lipoprotein (a) concentration. RESULTS--Men who suffered coronary heart disease had significantly higher serum lipoprotein (a) concentrations than controls (mean difference 105 mg/l; 95% confidence interval 18 to 192 mg/l). Men with the highest fifth of serum lipoprotein (a) concentrations (cut off point 365 mg/l) suffered a coronary heart disease rate which was more than twice that of men with the lowest four fifths of concentrations. Logistic regression analysis showed the serum lipoprotein (a) concentration to be significantly associated with coronary heart disease independently of other risk factors. CONCLUSION--The serum lipoprotein (a) concentration in middle aged men is an independent risk factor for subsequent myocardial infarction or death from coronary heart disease.

[1]  E. Boerwinkle,et al.  Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. , 1990, The New England journal of medicine.

[2]  G. Assmann,et al.  Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. , 1990, Clinical chemistry.

[3]  G. Utermann,et al.  The mysteries of lipoprotein(a). , 1989, Science.

[4]  G. Hallmans,et al.  Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population. , 1989, Atherosclerosis.

[5]  A. Hamsten,et al.  Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid , 1989, Journal of internal medicine.

[6]  M. Dietel,et al.  Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. , 1989, Arteriosclerosis.

[7]  M. Seishima,et al.  Transient changes of serum lipoprotein(a) as an acute phase protein. , 1989, Atherosclerosis.

[8]  S. Pizzo,et al.  Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. , 1989, Biochemistry.

[9]  S. Pizzo,et al.  Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. , 1989, Biochemistry.

[10]  G. Hoefler,et al.  Lipoprotein Lp(a): A Risk Factor for Myocardial Infarction , 1988, Arteriosclerosis.

[11]  L. Hunt,et al.  APOLIPOPROTEINS (a), AI, AND B AND PARENTAL HISTORY IN MEN WITH EARLY ONSET ISCHAEMIC HEART DISEASE , 1988, The Lancet.

[12]  E. Chen,et al.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen , 1987, Nature.

[13]  G. Utermann,et al.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. , 1987, The Journal of clinical investigation.

[14]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[15]  W. Kohr,et al.  Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Jürgens,et al.  Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. , 1987, Neurology.

[17]  V. Armstrong,et al.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. , 1986, Atherosclerosis.

[18]  N. Morton,et al.  Lp(a) lipoprotein as a risk factor for myocardial infarction. , 1986, JAMA.

[19]  A. Gotto,et al.  CORONARY ARTERY DISEASE Association of levels of lipoprotein Lp ( a ) , plasma lipids , and other lipoproteins with coronary artery disease documented by angiography , 2022 .

[20]  K. Pfeiffer,et al.  Lipoprotein(a) as a strong indicator for cerebrovascular disease. , 1986, Stroke.

[21]  M. Kameyama,et al.  Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. , 1986, Atherosclerosis.

[22]  L. Beilin,et al.  Effects of a lacto-ovo vegetarian diet on serum concentrations of cholesterol, triglyceride, HDL-C, HDL2-C, HDL3-C, apoprotein-B, and Lp(a). , 1984, The American journal of clinical nutrition.

[23]  E Marth,et al.  Lipoprotein Lp(a) and the risk for myocardial infarction. , 1981, Atherosclerosis.

[24]  L. Wilhelmsen,et al.  Registration of myocardial infarction in the city of Göteborg, Sweden. , 1975, Journal of chronic diseases.

[25]  K. Walton,et al.  A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. , 1974, Atherosclerosis.

[26]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .